Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26327731 | 0.83 | LMNA (0.43) | LMNACHRM1TDP1ALDH1A1CYP1A2 | |
| SCHEMBL26327722 | 0.82 | DRD2 (0.43) | LMNATDP1ALDH1A1 | |
| SCHEMBL25439817 | 0.81 | SIGMAR1 (0.51) | SIGMAR1KDM4ETAAR1 | |
| SCHEMBL7342963 | 0.79 | SIGMAR1 (0.56) | SIGMAR1KDM4ETAAR1TDP1ALDH1A1 | |
| SCHEMBL26326790 | 0.77 | LMNA (0.49) | LMNACHRM1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL26327619 | 0.75 | LMNA (0.50) | LMNACHRM1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL16732283 | 0.75 | LMNA (0.50) | LMNATDP1ALDH1A1 | |
| SCHEMBL2478291 | 0.74 | ALOX5 (0.43) | — | |
| SCHEMBL9395007 | 0.74 | LMNA (0.49) | LMNATDP1ALDH1A1CYP1A2 | |
| SCHEMBL26327797 | 0.73 | LMNA (0.45) | LMNACHRM1ALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | PNMT, NCL, NPM1 | SIGMAR1 2707/4885LMNA 167/4885CHRM1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.